Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 10, 2024, titled "Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".